{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:01:58Z","timestamp":1761897718437,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jfo.2021.08.005","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T07:29:21Z","timestamp":1651217361000},"page":"612-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Toxicit\u00e9 oculaire des th\u00e9rapies cibl\u00e9es anti-MEK et anti-BRAF dans le traitement des m\u00e9lanomes cutan\u00e9s m\u00e9tastatiques"],"prefix":"10.1016","volume":"45","author":[{"given":"E.","family":"Fauviaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3934-3671","authenticated-orcid":false,"given":"V.","family":"Promelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-8175","authenticated-orcid":false,"given":"V.","family":"Boucenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6934-6531","authenticated-orcid":false,"given":"B.","family":"Jany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.H.","family":"Errera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-0340","authenticated-orcid":false,"given":"M.","family":"Delbarre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3243-2436","authenticated-orcid":false,"given":"W.","family":"Boucenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2021.08.005_bib0100","article-title":"Situation \u00e9pid\u00e9miologique du m\u00e9lanome cutan\u00e9 en France et impact en termes de pr\u00e9vention","volume":"2","author":"Cherie-Challine","year":"2004","journal-title":"Bull Epidemiol Hebdo"},{"key":"10.1016\/j.jfo.2021.08.005_bib0105","first-page":"572","article-title":"Survival rates of patients with metastatic malignant melanoma","volume":"7","author":"Sandru","year":"2014","journal-title":"J Med Life"},{"key":"10.1016\/j.jfo.2021.08.005_bib0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1758834012466280","article-title":"Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm","volume":"5","author":"Khattak","year":"2013","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0115","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdu169","article-title":"Transient MEK inhibitor-associated retinopathy in metastatic melanoma","volume":"25","author":"Urner-Bloch","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0120","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.jfo.2021.08.005_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2015.07.035","article-title":"Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series","volume":"160","author":"Niro","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0130","doi-asserted-by":"crossref","first-page":"629","DOI":"10.5301\/ejo.5000423","article-title":"Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma","volume":"24","author":"Agemy","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0135","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3892\/ijmm_00000191","article-title":"MEK\/ERK pathway mediates UVB-induced AQP1\u00a0downregulation and water permeability impairment in human retinal pigment epithelial cells","volume":"23","author":"Jiang","year":"2009","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.jfo.2021.08.005_bib0140","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaophthalmol.2014.976","article-title":"Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer","volume":"132","author":"McCannel","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0145","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.ophtha.2015.05.027","article-title":"Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma","volume":"122","author":"van Dijk","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2021.08.005_bib0150","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","article-title":"Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma","volume":"22","author":"Daud","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jfo.2021.08.005_bib0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12886-018-0861-8","article-title":"New features in MEK retinopathy","volume":"18","author":"Tyagi","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000501155","article-title":"MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants","volume":"6","author":"Francis","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0165","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/jop.2009.0060","article-title":"PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion","volume":"25","author":"Huang","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2021.08.005_bib0170","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamaophthalmol.2016.0090","article-title":"Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer","volume":"134","author":"Weber","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000446845","article-title":"Risk of ophthalmic adverse effects in patients treated with MEK Inhibitors: a systematic review and meta-analysis","volume":"57","author":"Alves","year":"2017","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jfo.2021.08.005_bib0180","first-page":"130","article-title":"MEK inhibitor-associated retinopathy\u00a0(MEKAR) in metastatic melanoma: Long-term ophthalmic effects","volume":"65","author":"Urner-Bloch","year":"2016","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.jfo.2021.08.005_bib0185","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12886-017-0541-0","article-title":"Ocular toxicity due to Trametinib and Dabrafenib","volume":"17","author":"Sarny","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2021.08.005_bib0095","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551221005398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551221005398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:18:21Z","timestamp":1759259901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551221005398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0181551221005398"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2021.08.005","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9 oculaire des th\u00e9rapies cibl\u00e9es anti-MEK et anti-BRAF dans le traitement des m\u00e9lanomes cutan\u00e9s m\u00e9tastatiques","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}